This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
Retraction Note: SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment
Y. Sun, D. Zhu, F. Chen, M. Qian, H. Wei, W. Chen, J. Xu
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer-related gene regulation · RNA modifications and cancer · MicroRNA in disease regulation
Retraction to: Oncogene 10.1038/onc.2015.494, published online 11 January 2016
The Editor-in-Chief has retracted this article because the authors were not able to provide documentation of approval from an appropriate ethics committee. Additionally, concerns have also been raised about some of the data reported:
- In Figure 5c, the panels for Vehicle Control PSC27RAD and PSC27C appear to be duplicates.
- In Figure 6b, the panels for MIT-treated and Placebo-treated PC3/PSC27+IgG appear to overlap.
The Editor-in-Chief no longer has confidence in the reliability of this article’s finds and conclusions.
Y Sun has stated on behalf of all authors that they disagree with this retraction.